Marker Therapeutics Beat Consensus Estimates

Marker Therapeutics (MRKR) reported a loss of $0.09 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.25 per share on revenue of $0.60 million. The company beat consensus estimates by 64.00% while revenue fell 100.00% compared to the same quarter a year ago.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment and eradication of cancer, including metastatic cancer. The company's product pipeline consists of MultiTAA T Cell Therapy, TPIV200 and TPIV100/110 which are in clinical stage. Marker Therapeutics Inc., formerly known as TapImmune Inc., is based in FL, United States.